Background. Many patients with neurological disorders have an increased risk of infection and the severe course of COVID-19. Studies on positive predictors of seizure outcomes with the 2019 novel coronavirus disease remain limited.The objective is to study predictors for positive health outcomes after COVID infection in patients with epilepsy based on analysis of clinical observations.Design and Methods. Study design - the work is a part of a prospective observational study of seizure dynamics after COVID infection in patients with epilepsy.Results. The presented clinical observation demonstrates a positive health outcome after COVID infection in a young patient with the genetic generalized epilepsy with sustained clinical and electroencephalographic seizure remission on the next generation AED monotherapy (brivaracetam).Conclusion. Predictors for positive health outcome after the 2019 novel coronavirus disease in patients with epilepsy include a young age, absence of somatic comorbidities, seizure remission, modern drug use with no interaction among AEDs and antibiotics and antivirals for the coronavirus disease treatment. Despite the encouraging data on the favourable course of epilepsy in cases of developing COVID-19, further research is needed to continue.
Epilepsy and COVID-19: predictors of a positive outcome in patients with epilepsy (based on analysis of clinical cases)